Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
An. bras. dermatol
; 89(1): 154-156, Jan-Feb/2014. graf
Artigo
em Inglês
| LILACS
| ID: lil-703547
Biblioteca responsável:
BR1.1
ABSTRACT
The tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among others. Infliximab is a chimeric monoclonal antibody that specifically binds to soluble and transmembrane tumor necrosis factor alpha form blocking its action. In rheumatoid arthritis it is used because the cytokines that cause inflammation in this disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo after two months using infliximab. The event aims to alert to the existence of this adverse effect that can be induced with the use of this medication.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Artrite Reumatoide
/
Vitiligo
/
Antirreumáticos
/
Anticorpos Monoclonais
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
An. bras. dermatol
Assunto da revista:
Dermatologia
Ano de publicação:
2014
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Universidade do Oeste Paulista/BR